WCM
AMRX icon

Wedge Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Wedge Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-31,203
Closed -$62K – 428
2022
Q4 		$62K Hold
31,203
– – ﹤0.01% 418
2022
Q3 		$63K Hold
31,203
– – ﹤0.01% 403
2022
Q2 		$99K Buy
31,203
+1,176
+4% +$4.26K ﹤0.01% 404
2022
Q1 		$125K Buy
30,027
+214
+0.7% +$948 ﹤0.01% 415
2021
Q4 		$143K Buy
29,813
+6,763
+29% +$33.7K ﹤0.01% 406
2021
Q3 		$123K Buy
23,050
+4,448
+24% +$22.4K ﹤0.01% 399
2021
Q2 		$95K Buy
+18,602
New +$106K ﹤0.01% 392

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Wedge Capital Management's AMRX Position: Q1 2023 in Review

Wedge Capital Management sold out of Amneal Pharmaceuticals (AMRX) in Q1 2023, closing a stake of 31,203 shares — an estimated $62K sold.

Wedge Capital Management first reported a position in AMRX in Q2 2021 and held it in 7 quarters. The position peaked at $143K in Q4 2021. 144 funds tracked by Wall St. Rank hold AMRX as of Q1 2023.

  • Wedge Capital Management reported no remaining Amneal Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Wedge Capital Management sold 31,203 Amneal Pharmaceuticals shares in Q1 2023, an estimated $62K.
  • Wedge Capital Management first reported a position in Amneal Pharmaceuticals in Q2 2021 and held it in 7 quarters.
  • Wedge Capital Management's Amneal Pharmaceuticals position peaked at $143K in Q4 2021.
  • 144 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2023.

Based on Wedge Capital Management's 13F filing for Q1 2023, filed 11 Apr 2023.